Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-Year follow-up

Journal of Clinical Oncology

Volumn 22, Issue 23, 2004, Pages 4659-4664

  Czuczman, Myron S ^a   Weaver, Robin ^a   Alkuzweny, Baha ^a   Berlfein, Judy ^a   Grillo López, Antonio J ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL;

ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CANCER REGRESSION; CLINICAL ARTICLE; FOLLOW UP; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; FOLLICULAR LYMPHOMA; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEEDLE BIOPSY; PATHOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LOW-GRADE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PATIENT SELECTION; PREDNISOLONE; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 13244288836     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.020     Document Type: Article

References (25)

1. Fisher R, Gaynor E, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
2. Gordon L, Harrington D, Andersen J, et al: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 327: 1342-1349, 1992
3. Grillo-López AJ: Rituximab (Rituxan/ MabThera): The first decade (1993-2003). Expert Rev Anticancer Ther 3:767-779, 2003
4. Czuczman MS, Grillo-López AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
5. Vose JM, Link BK, Grossbard ML, et al: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001
6. Coiffier B, Lepage E, Briére J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
7. Habermann TM, Weller EA, Morrison VA, et al: Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large b-cell lymphoma (DLBCL). Blood 102:6a, 2003 (abstr 8)
8. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253, 1999
9. Hiddemann W, Dreyling MH, Forstpointner R, et al: Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). Blood 102:104a, 2003 (abstr 352)
10. Marcus R, Imrie K, Belch A, et al: An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma. Blood 102:28a, 2003 (abstr 87)
11. Colombat P, Solal-Celigny P, Roy P: Validity of the Follicular Lymphoma International Prognostic Index in all age groups. Blood 100:770a, 2002 (abstr 3046)
12. Czuczman MS, Fallon A, Mohr A, et al: Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29: 36-40, 2002
13. Vitolo U, Boccomini C, Ladetto M, et al: High clinical and molecular response rates in elderly patients with advanced stage follicular lymphoma treated at diagnosis with a brief chemo-immunotherapy FND + rituximab. Blood 100:359a-360a, 2002 (abstr 1392)
14. Davis TA, Maloney DG. Grillo-López AJ, et al: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon alfa-2a. Clin Cancer Res 6:2644-2652, 2000
15. van der Kolk LE, Grillo-Lopez AJ, Baars JW, et al: Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: Final report on safety and efficacy. Leukemia 17:1658-1664, 2003
16. van der Kolk LE, de Haas M, Grillo-Lopez AJ, et al: Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukemia 16:693-699, 2002
17. McLaughlin P, Grillo-López AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program. J Clin Oncol 16:2825-2833, 1998
18. Grillo-López AJ: Monoclonal antibody therapy for B-cell lymphoma. Int J Hematol 76:385-393, 2002
19. Grillo-López AJ: AntiCD20 mAbs: Modifying therapeutic strategies and outcomes in the treatment of lymphoma patients. Expert Rev Anticancer Ther 2:323-329, 2002
20. Czuczman MS, Younes A, Moore JO, et al: Interim results from a phase I/I study of anti-CD80 antibody (IDEC-114) therapy for follicular NHL. Proc Am Soc Clin Oncol 22:574, 2003 (abstr 2310)
21. Gordon LI, Moore JO, Cheson BD, et al: Phase I results from a multicenter trial of galiximab (anti-CD80 antibody, IDEC-114) in combination with rituximab for the treatment of follicular lymphoma. Blood 102:307b, 2003 (abstr 4951)
22. Grillo-López AJ: Zevalin: The first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2:485-493, 2002
23. Grillo-López AJ: A model for the breadth and depth of clinical effect observed with rituximab and Zevalin in NHL patients. Blood 100: 310b, 2002 (abstr 4780)
24. Armitage JO, Leonard JP, Greogory SA, et al: The effectiveness of tositumomab and iodine 131 tositumomab in relapsed/refractory follicular grade 1/2 and small lymphocytic non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 23: 573a, 2004 (abstr 6573)
25. Gordon LI, Molina A, Witzig T, et al: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood 103:4429-4431, 2004